HC Wainwright Has Positive Forecast for CRSP FY2026 Earnings

CRISPR Therapeutics AG (NASDAQ:CRSP) – Equities research analysts at HC Wainwright raised their FY2026 EPS estimates for CRISPR Therapeutics in a research note issued on Wednesday, August 5th. HC Wainwright analyst M. Kapoor now anticipates that the company will post earnings of ($4.53) per share for the year, up from their previous forecast of ($4.67). HC Wainwright has a “Buy” rating and a $80.00 price objective on the stock. The consensus estimate for CRISPR Therapeutics’ current full-year earnings is ($4.65) per share. HC Wainwright also issued estimates for CRISPR Therapeutics’ Q4 2027 earnings at ($1.24) EPS and FY2027 earnings at ($4.98) EPS.

A number of other equities research analysts have also issued reports on the company. Sanford C. Bernstein increased their price target on CRISPR Therapeutics from $50.00 to $56.00 and gave the stock a “market perform” rating in a research note on Wednesday, May 13th. Citigroup boosted their price objective on CRISPR Therapeutics from $82.00 to $88.00 and gave the company a “buy” rating in a research report on Tuesday. Morgan Stanley set a $60.00 price objective on CRISPR Therapeutics and gave the stock an “equal weight” rating in a research note on Thursday, June 11th. UBS Group set a $80.00 target price on CRISPR Therapeutics in a research report on Friday, June 12th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of CRISPR Therapeutics in a research note on Friday, July 17th. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, CRISPR Therapeutics has an average rating of “Moderate Buy” and an average target price of $68.06.

CRISPR Therapeutics Stock Down 1.5%

CRSP opened at $51.64 on Friday. The company has a debt-to-equity ratio of 0.34, a quick ratio of 17.96 and a current ratio of 17.85. CRISPR Therapeutics has a fifty-two week low of $44.12 and a fifty-two week high of $78.48. The firm’s fifty day moving average is $52.42 and its 200 day moving average is $52.30. The stock has a market cap of $4.99 billion, a price-to-earnings ratio of -10.85 and a beta of 1.74.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings data on Tuesday, June 30th. The company reported ($0.94) earnings per share (EPS) for the quarter. The firm had revenue of $10.18 million during the quarter. CRISPR Therapeutics had a negative return on equity of 24.39% and a negative net margin of 3,368.72%.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Cerity Partners LLC raised its position in shares of CRISPR Therapeutics by 3.0% in the second quarter. Cerity Partners LLC now owns 6,541 shares of the company’s stock worth $318,000 after acquiring an additional 190 shares during the period. Peapack Gladstone Financial Corp boosted its stake in shares of CRISPR Therapeutics by 3.0% during the 2nd quarter. Peapack Gladstone Financial Corp now owns 6,973 shares of the company’s stock worth $339,000 after acquiring an additional 200 shares in the last quarter. Allworth Financial LP grew its position in shares of CRISPR Therapeutics by 2.7% during the 4th quarter. Allworth Financial LP now owns 9,550 shares of the company’s stock valued at $501,000 after acquiring an additional 249 shares during the period. Meeder Advisory Services Inc. grew its position in shares of CRISPR Therapeutics by 6.6% during the 4th quarter. Meeder Advisory Services Inc. now owns 4,392 shares of the company’s stock valued at $230,000 after acquiring an additional 270 shares during the period. Finally, Hedges Asset Management LLC increased its stake in shares of CRISPR Therapeutics by 1.2% in the 4th quarter. Hedges Asset Management LLC now owns 22,775 shares of the company’s stock valued at $1,194,000 after purchasing an additional 275 shares in the last quarter. Hedge funds and other institutional investors own 69.20% of the company’s stock.

Insiders Place Their Bets

In other CRISPR Therapeutics news, insider Naimish Patel sold 3,786 shares of CRISPR Therapeutics stock in a transaction on Friday, May 29th. The shares were sold at an average price of $55.62, for a total value of $210,577.32. Following the sale, the insider directly owned 19,357 shares in the company, valued at approximately $1,076,636.34. The trade was a 16.36% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 5.20% of the company’s stock.

Key Headlines Impacting CRISPR Therapeutics

Here are the key news stories impacting CRISPR Therapeutics this week:

• Positive Sentiment: Piper Sandler reaffirmed its Buy rating, signaling continued confidence in CRISPR Therapeutics’ development pipeline and long-term commercial potential. Piper Sandler Reaffirms Their Buy Rating on CRISPR Therapeutics AG
• Positive Sentiment: Bullish commentary highlighted potential CASGEVY sales growth and expansion into in vivo gene editing through CTX310, which could broaden CRSP’s future revenue opportunities if clinical and commercial milestones are achieved. CRISPR Strong Buy CASGEVY Sales Growth and In Vivo Expansion With CTX310
• Neutral Sentiment: Brookline Capital Markets made mixed revisions: its Q3 2026 loss estimate improved slightly to $1.30 per share from $1.31, while its FY2027 loss estimate improved to $4.51 from $5.05. However, the firm still expects CRSP to remain unprofitable in 2026 and 2027.
• Negative Sentiment: Brookline reduced its Q4 2026 EPS estimate to a loss of $1.87 from $1.69 and lowered its FY2026 estimate to a loss of $5.63 from $5.36. Both forecasts are weaker than the broader current-year consensus loss estimate of $4.90, potentially weighing on sentiment.
• Negative Sentiment: The same analyst modestly cut projected profits for FY2028, FY2029 and FY2030, suggesting a slightly less optimistic view of CRSP’s long-term earnings ramp. Despite those reductions, the estimates still imply a transition from losses to profitability beginning in FY2028.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent ?-thalassemia in collaboration with Vertex Pharmaceuticals.